Company Overview and News
Resverlogix (OTCPK:RVXCF) recently announced that the FDA has accepted the statistical analysis plan and endpoints for the large-scale Phase 3 trial of assessment of cardiovascular benefits of its lead candidate apabetalone. The projected endpoint of the study is the reduction of major adverse cardiovascular events (MACE) in a high cardiovascular risk in type 2 diabetes population. The same population often also displayed low levels of high density lipoproteins (HDL).
CTRV AMGN RVXCF MTFB APTO MTFB APS LLY TRIL RYTM GSK MYL MTFBF INSY LIVN CHMA
Morgan Stanley, Cowen, Wells Fargo and Wedbush Pacgrow will help the company sell 22,313,687 shares at $16-$18 per share.
WFCNP MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA ONCE WFC.PRT SHPG MYL WFC.PRR WFC.PRQ SLN WFC.PRP WFC.PRO WFC.PRN WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS EPIX VBIV SNY BMRN ARDX MS.PRI EPI MS.PRK NVS PLX PFE
Unless you’ve been living under a rock, you know that the narrative surrounding broad markets — it’s been one of strife since late January until the recent rally. Volatility spiked and the S&P 500 Index still sits almost 3% below late-January highs.
LRCX TEVA GS.PRB GS.PRA CDNS DLTR GLSSP FEYE AMZN ALXN AMAT CELG AVGO EBAY SNAP JBK QQQ TTWO TFG VRX CHKP CA CTSH MAR GS.PRJ GS.PRI BABA EXPE ORBK GOOGL GS.PRD GS.PRC QCOM GS.PRN GS.PRK JD XLNX FB ULTA ADP MNST TEVVF PYPL NFLX AMD NVDA GOOG KLAC ATVI MAR.WI GS MYL AAPL KO PAYX IBM EA CELGZ GSC GS.PRICL PANW GSJ BKNG ADPVV TEVJF MU DG MNK BRCM GJS
GlaxoSmithKline (NYSE:GSK) is one of the world's largest pharmaceutical companies. Its headquarters are in London, England. It pays a hefty dividend. Its array of products is quite diverse, including consumer healthcare products as well as new, cutting-edge medicines. In this article I will analyze whether the dividend is safe given Glaxo's potential for revenue growth (or decline).
MYL AMGN GILD BIIB AGEN CELG GSK NVS GSK
The Canada-based drug company is changing its name on Jul. 1 to Bausch Health Corp. That, along with the new ticker symbol (BHC), is supposed to put the company’s past behind it once and for all, leading to growth and profit for investors.
The bioscience market traded slightly south with an overall skittish sentiment. Despite some key losers, many equities under our coverage continued to break the trend to post further gains.
CDTX MYL PRTK SPPI MDCO MLNT IBB AKAO XBI NVAX
Iovance Biotherapeutics (NASDAQ:IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2 trial in metastatic melanoma using tumor-infiltrating lymphocytes (‘TIL). These are T cells derived from the patients' tumors.
NKTR DCPH VXRT LOXO NWBO PODD MRSN SHPG BPMC MYL IMMU IDRA IOVA CTMX KITE CYHHZ BMY CYH AMAG GILD NWBOW PTN PDM K JNCE MRK GHDX ALNY
Mylan N.V. (NASDAQ: MYL) saw its shares make a handy gain early on Tuesday after the U.S. Food and Drug Administration (FDA) announced a key approval. The agency approved Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Neulasta (pegfilgrastim).
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to MYL / Mylan N.V. on message board site Silicon Investor.
|Amylinu0027s Projected Annual EPS||AMYLIN PHARM.|
|Mylan Labs||AMLN: Amylin Pharmaceuticals|
|MVL.VSE - Mylan Ventures Info|
as of ET